These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19960438)

  • 1. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
    Fischgräbe J; Götte M; Michels K; Kiesel L; Wülfing P
    Int J Cancer; 2010 Aug; 127(3):696-706. PubMed ID: 19960438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disrupting EGFR-HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: Quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome.
    Ujlaky-Nagy L; Szöllősi J; Vereb G
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.
    Nava M; Dutta P; Zemke NR; Farias-Eisner R; Vadgama JV; Wu Y
    BMC Med Genomics; 2019 Feb; 12(1):32. PubMed ID: 30736768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.
    Kohrt HE; Houot R; Weiskopf K; Goldstein MJ; Scheeren F; Czerwinski D; Colevas AD; Weng WK; Clarke MF; Carlson RW; Stockdale FE; Mollick JA; Chen L; Levy R
    J Clin Invest; 2012 Mar; 122(3):1066-75. PubMed ID: 22326955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the function of the HER2 oncogene in human cancer therapeutics.
    Moasser MM
    Oncogene; 2007 Oct; 26(46):6577-92. PubMed ID: 17486079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells.
    Wan J; Sazani P; Kole R
    Int J Cancer; 2009 Feb; 124(4):772-7. PubMed ID: 19035464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H
    Kaneko MK; Suzuki H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2024 Apr; 43(2):35-43. PubMed ID: 38563783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-770-5p-induced cellular switch to sensitize trastuzumab resistant breast cancer cells targeting HER2/EGFR/IGF1R bidirectional crosstalk.
    Noyan S; Gür Dedeoğlu B
    Turk J Biol; 2024; 48(2):153-162. PubMed ID: 39051060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab Blocks the Receiver Function of HER2 Leading to the Population Shifts of HER2-Containing Homodimers and Heterodimers.
    Zhao J; Mohan N; Nussinov R; Ma B; Wu WJ
    Antibodies (Basel); 2021 Feb; 10(1):. PubMed ID: 33557368
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Li F; Wu Y; Shi Y; Liu X; Xie Y; Liu S
    Acta Biochim Biophys Sin (Shanghai); 2024 Mar; 56(3):462-473. PubMed ID: 38379418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody.
    Oganesyan V; Peng L; Bee JS; Li J; Perry SR; Comer F; Xu L; Cook K; Senthil K; Clarke L; Rosenthal K; Gao C; Damschroder M; Wu H; Dall'Acqua W
    J Biol Chem; 2018 Jun; 293(22):8439-8448. PubMed ID: 29669810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and delivery strategies of the dual Rac/Cdc42 inhibitor MBQ-167 in HER2 overexpressing breast cancer.
    Velázquez-Vega LE; Rivera-Robles M; Sánchez-Álvarez AO; Vivas-Mejía PE; Aponte-Reyes M; Cruz-Collazo AM; Grafals-Ruiz N; Dorta-Estremera S; Hernández-O'Farrill E; Vlaar CP; Dharmawardhane S
    Transl Oncol; 2024 Jun; 44():101928. PubMed ID: 38489873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Permissive role of endothelin receptors in tumor metastasis.
    Said N; Theodorescu D
    Life Sci; 2012 Oct; 91(13-14):522-7. PubMed ID: 22846215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. H
    Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
    Exp Ther Med; 2020 Aug; 20(2):846-853. PubMed ID: 32765652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of MALAT1 Promotes Trastuzumab Resistance in HER2 Overexpressing Breast Cancers.
    Wu Y; Sarkissyan M; Ogah O; Kim J; Vadgama JV
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to Trastuzumab in Breast Cancer.
    Pohlmann PR; Mayer IA; Mernaugh R
    Clin Cancer Res; 2009 Dec; 15(24):7479-7491. PubMed ID: 20008848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy.
    Fatima I; Rahdar A; Sargazi S; Barani M; Hassanisaadi M; Thakur VK
    J Funct Biomater; 2021 Dec; 12(4):. PubMed ID: 34940554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.
    Gray MA; Tao RN; DePorter SM; Spiegel DA; McNaughton BR
    Chembiochem; 2016 Jan; 17(2):155-8. PubMed ID: 26556305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells.
    Vanderhoeven F; Redondo AL; Martinez AL; Vargas-Roig LM; Sanchez AM; Flamini MI
    Oncotarget; 2018 May; 9(41):26527-26542. PubMed ID: 29899874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production, expression, and function of dual-specific monoclonal antibodies in a single plant.
    Jin C; Kang YJ; Park SR; Oh YJ; Ko K
    Planta; 2023 Dec; 259(1):15. PubMed ID: 38071691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.